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disorders, the effectiveness of treating IPVs with SEPS has been madden-
ingly difficult to prove.
Treatment of Proximal Deep-Vein Thrombosis with the Oral Direct
Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT
(Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute
Symptomatic Deep-Vein Thrombosis) Study
Agnelli G, Gallus A, Goldhaber SZ, and the ODIXa-DVT Study Investiga-
tors. Circulation 2007;116:180-7.
Conclusion: The orally active direct factor Xa inhibitor rivaroxaban
appears effective in treatment of proximal deep-vein thrombosis (DVT).
Summary: There is a major need for an orally active anticoagulant that
does not require long-term monitoring or dose adjustment. A potential
anticoagulant meeting those requirements is rivaroxaban (BAY
59-7939). This is an oral direct factor Xa inhibitor currently under
clinical development. This study was a parallel-group, randomized, dose-
ranging, phase II trial in patients with proximal DVT. The study was
designed to evaluate the safety and efficacy of BAY 59-7939, using doses
of 10, 20, or 30 mg twice daily (BID) or 40 mg once daily compared with
enoxaparin, 1 mg/kg BID, followed by a vitamin K antagonist. Treat-
ments were administered for 12 weeks. The primary end point was
“improvement in thrombotic burden” at 3 weeks. This was assessed by
quantitative compression duplex ultrasonography and defined as 4-
point improvement in a thrombus score without recurrent symptomatic
DVT or a DVT-related death.
The primary efficacy end point was achieved in 53% (53 in 100) patients
treated with 10 mg of rivaroxaban. Primary efficacy end points were also
achieved in 59.2% (58 of 98), 56.9% (69 of 109), and 43.8% (49 of 112)
patients receiving 20 or 30 mg BID or 40 mg once daily of rivaroxaban. In
the 109 patients treated with enoxaparin and a vitamin K antagonist, the
primary end point was achieved in 45.9% (50 of 109) patients. There was no
significant trend in the dose-response relationship between the primary
efficacy end point and rivaroxaban BID (P  .67). In the patients receiving
10 or 20 mg of rivaroxaban BID or 40 mg once daily, major bleeding was
observed in 1.7%. In the patients receiving 30mg BID of rivaroxaban, major
bleeding occurred in 3.3%. There were no major bleeding events with an
enoxaparin and vitamin K antagonist.
Comment: This was essentially a phase II proof-of-concept trial of a
new oral anticoagulant. Clearly, a safe orally administered anticoagulant that
requires no monitoring would be a major step forward. The data justified
performance of a larger phase III evaluation. Although the mechanism of
action of rivaroxaban is different than ximelagatran, the hepatic toxicity
associated with ximelagatran (Drug Safety 2005;28:351-70) mandates in-
tense surveillance for liver toxicity in a phase III study of rivaroxaban.
Effect of Perindopril on Large Artery Stiffness and Aortic Root Diam-
eter in Patients with Marfan Syndrome: A Randomized Controlled
Trial
Ahimastos A, Aggarwal A, D’Orsa K, et al. JAMA 2007;298:1539-47.
Conclusion: Perindopril reduces aortic stiffness and aortic root diam-
eter in patients with Marfan syndrome taking standard -blocker therapy.
Summary: Angiotensin-converting enzymes (ACE) can reduce arte-
rial stiffness. Aortic stiffness is increased in Marfan syndrome and con-
tributes to aortic dilatation and rupture. Traditionally, patients with
Marfan syndrome are treated with -blocker therapy. It is thought
-blockers induce reduction in pressure change in the aortic root,
thereby decreasing aortic wall stress. The rennin-angiotensin system may
lead to development of aortic stiffening and is perhaps a more direct
underlying pathophysiologic mechanism that results in aortic dilatation
and rupture in patients with Marfan syndrome.
The authors performed a double blind, randomized, placebo-controlled
trial of 17 patients with Marfan syndrome. The patients were aged 33  6
years and were on standard -blocker therapy. The trial was initiated in
January 2004 and completed in September 2006. Patients were adminis-
tered 8 mg/d of perindopril (n  10) or placebo (n  7) for 24 weeks.
Central and peripheral pulse wave velocities and systemic compliance were
used to measure arterial stiffness. Aortic root diameter was assessed with
transthoracic echocardiography.
Central arterial stiffness (increased systemic arterial compliance) was
decreased at 24 weeks in the perindopril group vs the placebo group (P 
.004). Arterial stiffness was also reduced peripherally as measured by in-
creased arterial compliance in the perindopril group vs placebo (P  .001).
Perindopril also reduced aortic root diameters relative to placebo in both
end-systole and end-diastole (P  .01 to P  .001 for all comparisons
between groups). Transforming growth factor- (TGF-), a contributor to
aortic degeneration in Marfan syndrome, was reduced by perindopril com-
pared with placebo (P  .01).
Comment:Data indicate that adjunct therapy using ACE inhibitors in
addition to -blockers reduces arterial stiffness and aortic root diameters in
patients with Marfan syndrome. The observed reduction in TGF- likely
occurs through reduced signaling of the angiotensin II type 1 and angioten-
sin II type 2 receptors. The study is limited by small sample size and short
duration. The findings are, however, sufficiently dramatic, and will likely
rapidly influence basic medical management of patients with Marfan syn-
drome.
Patent Foramen Ovale and Cryptogenic Stroke in Older Patients
Handke M, Harloff A, Olschewski M, et al. N Engl J Med 2007;357:
2262-8.
Conclusion: Paradoxical embolism is a cause of stroke both in patients
aged 55 and 55 years.
Summary: Routine diagnostic testing fails to diagnose the cause of
stroke in about 40% of patients (AnnNeuro 1989;25:382-90). The foramen
ovale remains patent in about one-fourth of the overall population. It may
facilitate stroke through paradoxic embolism. There is a known association
between cryptogenic stroke and a patent foramen ovale in patients aged55
years. This study sought to determine whether there was such an association
in patients aged 55 years.
There were 503 consecutive patients with stroke who were prospec-
tively examined. Of these, 276 served as control patients, in that they had a
known cause of stroke, and 227 patients had an unknown cause of stroke, or
cryptogenic stroke. The prevalence of a patent foramen ovale and patent
foramen ovale with concomitant atrial septal aneurysm, as determined by
transesophageal echocardiography (TEE), was examined. The authors also
examined data comparing 131 patients aged 55 years with 372 patients
aged 55 years.
Compared with patients with stroke of known cause, the prevalence of
a patent foramen ovale was greater in those with cryptogenic stroke in both
younger patients (43.9% vs 14.3%; odds ratio [OR], 4.70; 95% confidence
interval [CI], 1.89-11.68; P  .001) and older patients (28.3% vs 11.9%;
OR, 2.92; 95%CI, 1.70-5.01; P .001). Cryptogenic stroke was evenmore
strongly associated with the presence of a patent foramen ovale with con-
comitant atrial septal aneurysm compared with those patients with stroke of
known cause. This was true among both younger patients (13.4% vs 2.0%;
OR, 7.36; 95% CI, 1.01-326.6; P  .049) and older patients (15.2% vs
4.4%; OR, 3.88; 95% CI, 1.78-8.46; P  .001). Adjusting for plaque
thickness, coronary disease, age, and hypertension, the presence of a
patent foramen ovale was independently associated with cryptogenic
stroke in both the older patient group (OR, 3.00; 95% CI, 1.73-5.23;
P .001) and the younger patient group (OR, 3.70; 95% CI, 1.42-9.65;
P  .008).
Comment: The presence of patent foramen ovale decreases with
increasing age (Mayo Clin Proc 1984;59:17-20). Nevertheless, the data
indicate that a patent foramen ovale, especially with concomitant atrial septal
aneurysm, places patients at significant risk for stroke. Although current data
indicate this risk, they do not provide recommendations for treatment.
Currently, however, there are several ongoing randomized trials to deter-
mine appropriate therapy for patients with a patent foramen ovale. Evidence-
based treatment recommendations should therefore be available reasonably
soon.
Therapeutic Benefit of Low-Dose Clopidogrel in Patients Undergoing
Carotid Surgery is Linked to Variability in the Platelet Adenosine
Diphosphate Response and Patients’ Weight
Payne DA, Jones CI, Hayes PD, et al. Stroke 2007;38:2464-9.
Conclusion: The ability of one 75-mg dose of clopidogrel to reduce
transcranial Doppler (TCD)–detected embolization after carotid endarter-
ectomy (CEA) is achieved by clopidogrel-induced prevention of monocyte-
platelet aggregates.
Summary: The authors have previously shown that a single 75-mg
dose of clopidogrel can reduce TCD-detected embolization after CEA
(Circulation 2004;109:1476-81). It is, however, known that dosing of
clopidogrel at 75 mg/d produces only incremental effects in reducing
adenosine diphosphate (ADP)–mediated platelet activation, with maximum
reduction not occurring until after 7 days. This is contrast to the ability of a
300- to 600-mg loading dose of clopidogrel to produce rapid and pro-
nounced platelet inhibitory effects (Semin ThrombHemost 1999; 25 [suppl
2]: 15-19).
In this article, the authors sought to explain the mechanism of how
a single dose of clopidogrel reduces TCD-detected embolic events after
CEA. The study randomized 56 patients on long-term aspirin therapy
(150 mg/d) to 75 mg of clopidogrel or placebo before CEA. Platelet
activation and ADP responses, determined by flow cytometry and aggre-
gometry, were measured before and after drug administration and at the
end of surgery. There was a significant surgery-induced rise in platelet
activation in vivo. There was a rise in the percentage of monocyte-platelet
aggregates in patients given placebo that was not seen in patients
receiving clopidogrel. Platelet response was more pronounced after
surgery, and clopidogrel produced a significant reduction in platelet
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response to ADP (P  .01). The percentage of platelets binding fibrin-
ogen and the response to ADP was 76.53%  2.2% in the placebo group
vs 69.84% 3% in the clopidogrel group (P .002). Patients with higher
baseline responses to ADP showed the greatest response to clopidogrel.
Patient weight correlated negatively with the effect of clopidogrel (r 
0.57; P  .002).
Comment: Monocyte-platelet aggregates are an accurate indicator of
in vivo platelet activation. The elimination of the increase in monocyte-
platelet aggregates by a single dose of clopidogrel in patients undergoing
CEA appears to be a function of the ability of clopidogrel to provide a
significant reduction in the platelet response to ADP. The study is limited in
that it was only designed to measure a laboratory indicator of the antiplatelet
effect of clopidogrel. Trials assessing clinical end points potentially modifi-
able by clopidogrel in patients undergoing CEA are needed. Such trials will
need to be stratified according to baseline platelet reactivity and patient
weight.
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